Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04044664 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder
A Phase 2 study, sponsored by Aptinyx.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT04044664: Completed Phase 2 study, sponsored by Aptinyx.
NCT04044664 is a Phase 2 study that has completed, run by Aptinyx. The registered enrollment target is 160 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04044664, a Phase 2 study, has completed, sponsored by Aptinyx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
To evaluate the safety, tolerability, and response profile of NYX-783 in a Post-Traumatic Stress Disorder population.
Primary Outcome
CAPS-5 \[Clinician Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)\] is a structured interview for diagnosis and assessment of PTSD. The assessor combines information about frequency and intensity of an item into a severity rating (0-4). CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms. CAPS-5 symptom cluster severity scores are calculated by summing the individual item severity sc
Interventions
- DRUG Placebo oral capsule
- DRUG NYX-783
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2019-01-25 |
| Est. Completion | 2020-08-05 |
| Phase | Phase 2 |
What the finished NCT04044664 record still lists
NCT04044664 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT04044664 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04044664 about?
NCT04044664 is a clinical study titled "Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder". To evaluate the safety, tolerability, and response profile of NYX-783 in a Post-Traumatic Stress Disorder population.
What is the current status of trial NCT04044664?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2019-01-25. Estimated completion is 2020-08-05.
What interventions are being tested in trial NCT04044664?
The interventions under investigation include: Placebo oral capsule (DRUG), NYX-783 (DRUG).
Who is sponsoring clinical trial NCT04044664?
This trial is sponsored by Aptinyx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04044664's enrollment target sits among peer trials
160 422nd of 2000 higher than 1,559 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI